A Managed Care Lens on JAK Inhibitors for the Treatment of Myelofibrosis

A Managed Care Lens on JAK Inhibitors for the Treatment of Myelofibrosis is organized by Pharmacy Times Continuing Education (PTCE).,Release date: May 18, 2022,Expiration date: May 18, 2023,Description:,Myelofibrosis is a rare hematologic malignancy with related primary and secondary manifestations including polycythemia vera, essential thrombocythemia, and other myeloproliferative neoplasms. Mutations in the Janus kinase (JAK) 2 gene are present in approximately 50% of patients with myelofibrosis, and JAK inhibitors have since emerged as therapeutic targets. However, each JAK inhibitor has unique mechanisms of action and gene targets, making it important to distinguish their use in individual patients. This activity will examine the critical role of the pharmacist as part of the multidisciplinary team in determining disease- and patient-specific treatment plans to improve patient outcomes. Practical strategies for managed care professionals to incorporate approved and emerging JAK inhibitors into formularies for the treatment of myelofibrosis will also be discussed.,Educational Objectives:,At the completion of this activity, participants will be able to:,Explain the etiology, pathophysiology, and prognostic scoring system of myelofibrosis,Analyze the treatments for myelofibrosis along with the clinical data for Janus kinase inhibitors and pipeline-targeted therapies,Interpret the quality of life and impact of financial toxicity for patients with myelofibrosis and the resources available to assist this population